Sofinnova Investments, Inc. — 13F Holdings & Portfolio

CIK 1631134 · latest 13F-HR filed 2026-08-14

Sofinnova Investments, Inc. manages $1.93B in 13F-reported U.S. long-equity assets across 57 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are NTRA (21.76%), VERA (6.20%), GMAB (5.74%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 11 new positions and exited 19; 24 existing positions rose in reported value and 14 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$1.93B

Long-equity book

Holdings
57

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+11 / −19 / ↑24 / ↓14

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 59.8%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 27, 2026.

Assets Under Management
$5.37B
Discretionary
$5.37B
Employees
41
Accounts
20
Address
3000 SAND HILL ROAD
3-150
MENLO PARK, CA 94025
Phone
(650) 681-8420
Name Title / Status Ownership Type
AUBER, NATHALIE, MARIE ControlPARTNER AND CHIEF FINANCIAL OFFICER
since Jan 1998
5–10%Individual
AZAN, ALAIN, LOUIS ControlSHAREHOLDER
since Jun 1997
5–10%Individual
BRODY, JAMES, DENNIS ControlCHIEF COMPLIANCE OFFICER
since Oct 2016
Less than 5%Individual
DELBRIDGE, ERIC, HELMUT ControlGENERAL PARTNER, PUBLIC EQUITY
since May 2016
Less than 5%Individual
EKMAN, LARS, GOSTA ControlEXECUTIVE PARTNER, PRIVATE EQUITY
since Sep 2016
Less than 5%Individual
HEALY, JAMES, IRVIN ControlMANAGING PARTNER
since Jun 2000
50–75%Individual
KATABI, MAHA, MEHDI ControlGENERAL PARTNER
since Apr 2019
10–25%Individual
SHAHLAVI, HOOMAN, NO MIDDLE NAME ControlPARTNER AND CHIEF LEGAL OFFICER
since Feb 2007
5–10%Individual
Ownership & leadership changes · 13 filings with changes since Mar 30, 2012

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 20, 2025 filing
  • ChangedAUBER, NATHALIE, MARIE · title SHAREHOLDER, DIRECTOR AND CHIEF FINANCIAL OFFICER → PARTNER AND CHIEF FINANCIAL OFFICER
  • ChangedDELBRIDGE, ERIC, HELMUT · title DIRECTOR → GENERAL PARTNER, PUBLIC EQUITY
  • ChangedEKMAN, LARS, GOSTA · title BOARD OF DIRECTORS MEMBER, EXECUTIVE PARTNER → EXECUTIVE PARTNER, PRIVATE EQUITY
  • ChangedHEALY, JAMES, IRVIN · title SHAREHOLDER, DIRECTOR → MANAGING PARTNER
  • ChangedKATABI, MAHA, MEHDI · title SHAREHOLDER, DIRECTOR AND VICE PRESIDENT → GENERAL PARTNER
  • ChangedSHAHLAVI, HOOMAN, NO MIDDLE NAME · title SHAREHOLDER, SECRETARY AND CHIEF LEGAL OFFICER → PARTNER AND CHIEF LEGAL OFFICER
Mar 15, 2024 filing
  • AddedDELBRIDGE, ERIC, HELMUT · DIRECTOR · Less than 5% · control person
  • ChangedHEALY, JAMES, IRVIN · title SHAREHOLDER, DIRECTOR AND PRESIDENT → SHAREHOLDER, DIRECTOR
  • ChangedSHAHLAVI, HOOMAN, NO MIDDLE NAME · now a control person
Mar 29, 2023 filing
  • AddedEKMAN, LARS, GOSTA · BOARD OF DIRECTORS MEMBER, EXECUTIVE PARTNER · Less than 5% · control person
Sep 6, 2022 filing
  • No longer listedBHAGAT, SARAH, MANECK · SHAREHOLDER AND DIRECTOR · 10–25% · control person · listed since May 2017
Jun 23, 2021 filing
  • No longer listedPOWELL, MICHAEL, FRANK · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person · listed since Aug 1997
  • ChangedAUBER, NATHALIE, MARIE · ownership 10–25% → 5–10%
  • ChangedAZAN, ALAIN, LOUIS · ownership 10–25% → 5–10%
  • ChangedBHAGAT, SARAH, MANECK · ownership 5–10% → 10–25%
  • ChangedHEALY, JAMES, IRVIN · ownership 10–25% → 50–75%
  • ChangedKATABI, MAHA, MEHDI · ownership 5–10% → 10–25%
Mar 31, 2021 filing
  • AddedBHAGAT, SARAH, MANECK · SHAREHOLDER AND DIRECTOR · 5–10% · control person
  • AddedKATABI, MAHA, MEHDI · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 5–10% · control person
Feb 19, 2021 filing
  • No longer listedMEHRA, ANAND, NO MIDDLE NAME · SHAREHOLDER · 10–25% · control person · listed since May 2007
Mar 30, 2020 filing
  • ChangedSHAHLAVI, HOOMAN, NO MIDDLE NAME · title SHAREHOLDER, SECRETARY AND GENERAL COUNSEL → SHAREHOLDER, SECRETARY AND CHIEF LEGAL OFFICER
Feb 11, 2020 filing
  • ChangedMEHRA, ANAND, NO MIDDLE NAME · title SHAREHOLDER, DIRECTOR AND VICE PRESIDENT → SHAREHOLDER
Jan 31, 2018 filing
  • ChangedAZAN, ALAIN, LOUIS · title SHAREHOLDER AND DIRECTOR → SHAREHOLDER
Older changes (4 more filings)
Mar 3, 2017 filing
  • AddedBRODY, JAMES, DENNIS · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • AddedMEHRA, ANAND, NO MIDDLE NAME · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person
  • ChangedAUBER, NATHALIE, MARIE · ownership Less than 5% → 10–25%
  • ChangedSHAHLAVI, HOOMAN, NO MIDDLE NAME · title SECRETARY AND GENERAL COUNSEL → SHAREHOLDER, SECRETARY AND GENERAL COUNSEL; ownership Less than 5% → 5–10%
Mar 30, 2016 filing
  • No longer listedAKKARAJU, SRINIVAS · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person · listed since Jun 2013
Mar 27, 2014 filing
  • No longer listedBUATOIS, ERIC, PIERRE · SHAREHOLDER AND VICE PRESIDENT · 10–25% · control person · listed since Aug 2001
  • No longer listedKONG, GARHENG, ALBERT · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person · listed since Sep 2010
  • AddedAKKARAJU, SRINIVAS · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person
Mar 30, 2012 filing (earliest on record)
  • ListedAUBER, NATHALIE, MARIE · SHAREHOLDER, DIRECTOR AND CHIEF FINANCIAL OFFICER · Less than 5% · control person
  • ListedAZAN, ALAIN, LOUIS · SHAREHOLDER AND DIRECTOR · 10–25% · control person
  • ListedBUATOIS, ERIC, PIERRE · SHAREHOLDER AND VICE PRESIDENT · 10–25% · control person
  • ListedHEALY, JAMES, IRVIN · SHAREHOLDER, DIRECTOR AND PRESIDENT · 10–25% · control person
  • ListedKONG, GARHENG, ALBERT · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person
  • ListedPOWELL, MICHAEL, FRANK · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person
  • ListedSHAHLAVI, HOOMAN, NO MIDDLE NAME · SECRETARY AND GENERAL COUNSEL · Less than 5%

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Top Adds (vs prior quarter)

Show all 24 →

Top Trims

Show all 14 →

Sofinnova Investments, Inc. Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 Natera Inc NTRA 632307104 $420.8M 21.76% 1,550,280 SH
2 Vera Therapeutics Inc VERA 92337R101 $119.9M 6.20% 2,793,987 SH
3 Genmab A/S GMAB 372303206 $111.1M 5.74% 4,045,215 SH
4 Jazz Pharmaceuticals PLC JAZZ G50871105 $88.0M 4.55% 365,341 SH
5 Rapport Therapeutics Inc RAPP 75383L102 $79.4M 4.10% 1,904,408 SH
6 Seaport Therapeutics Inc SPTX 81221K108 $77.4M 4.00% 3,564,871 SH
7 Arrivent BioPharma Inc AVBP 04272N102 $58.9M 3.05% 1,696,752 SH
8 Ultragenyx Pharmaceutical In RARE 90400D108 $57.3M 2.96% 1,717,505 SH
9 BioAge Labs Inc BIOA 09077V100 $56.2M 2.91% 2,293,788 SH
10 Bristol-Myers Squibb Co BMY 110122108 $50.5M 2.61% 876,970 SH
11 Supernus Pharmaceuticals SUPN 868459108 $48.2M 2.49% 1,036,328 SH
12 Rhythm Pharmaceuticals Inc RYTM 76243J105 $45.3M 2.34% 408,027 SH
13 Gilead Sciences Inc GILD 375558103 $43.3M 2.24% 343,100 SH
14 United Therapeutics Corp Del UTHR 91307C102 $41.4M 2.14% 76,489 SH
15 Cogent Biosciences Inc COGT 19240Q201 $40.1M 2.07% 1,035,148 SH
16 Axsome Therapeutics Inc. AXSM 05464T104 $39.3M 2.03% 160,429 SH
17 Immatics N.V IMTX N44445109 $37.2M 1.92% 3,669,346 SH
18 Dyne Therapeutics Inc DYN 26818M108 $36.8M 1.90% 1,658,384 SH
19 Immunome Inc IMNM 45257U108 $36.5M 1.88% 1,720,316 SH
20 IDEAYA Biosciences Inc IDYA 45166A102 $34.5M 1.78% 925,119 SH
21 Anaptysbio Inc ANAB 032724106 $33.3M 1.72% 493,536 SH
22 Nektar Therapeutics NKTR 640268306 $32.9M 1.70% 471,763 SH
23 Pharvaris N V PHVS N69605108 $30.5M 1.58% 881,299 SH
24 Arcus Biosciences Inc RCUS 03969F109 $29.2M 1.51% 945,690 SH
25 Inhibrx Biosciences Inc INBX 45720N103 $28.7M 1.48% 303,103 SH
26 BioMarin Pharmaceutical Inc BMRN 09061G101 $20.5M 1.06% 358,568 SH
27 Veradermics Inc MANE 922967104 $18.3M 0.95% 148,993 SH
28 Alcon AG ALC H01301128 $17.2M 0.89% 255,824 SH
29 Insmed Inc INSM 457669307 $16.9M 0.87% 158,398 SH
30 Ultragenyx Pharmaceutical In Call RARE 90400D108 $16.7M 0.86% 500,000 SH
31 Intuitive Surgical Inc Call ISRG 46120E602 $15.9M 0.82% 40,000 SH
32 Globus Med Inc Call GMED 379577208 $15.8M 0.82% 200,000 SH
33 Edgewise Therapeutics Inc EWTX 28036F105 $15.5M 0.80% 380,923 SH
34 Exelixis Inc Put EXEL 30161Q104 $13.8M 0.72% 254,200 SH
35 Nurix Therapeutics Inc NRIX 67080M103 $12.7M 0.66% 524,098 SH
36 Design Therapeutics Inc DSGN 25056L103 $12.5M 0.65% 865,135 SH
37 Definium Therapeutics Inc DFTX 24477V105 $12.0M 0.62% 255,903 SH
38 First Tracks Biotherapeutics TRAX 337185102 $11.4M 0.59% 565,199 SH
39 Abbott Laboratories ABT 002824100 $11.2M 0.58% 122,998 SH
40 Disc Medicine Inc IRON 254604101 $10.7M 0.55% 146,239 SH
41 Tenax Therapeutics Inc TENX 88032L605 $7.3M 0.38% 500,039 SH
42 Sionna Therapeutics Inc SION 829401108 $6.4M 0.33% 144,432 SH
43 Absci Corporation ABSI 00091E109 $3.9M 0.20% 337,400 SH
44 Mirum Pharmaceuticals Inc MIRM 604749101 $3.2M 0.17% 27,591 SH
45 Jade Biosciences Inc JBIO 008064206 $2.4M 0.12% 107,391 SH
46 Savara Inc SVRA 805111101 $2.2M 0.12% 364,763 SH
47 Praxis Precision Medicines I PRAX 74006W207 $2.2M 0.11% 6,440 SH
48 Septerna Inc SEPN 81734D104 $1.6M 0.08% 47,506 SH
49 Onkure Therapeutics Inc OKUR 68277Q105 $1.5M 0.08% 321,692 SH
50 Sagimet Biosciences Inc SGMT 786700104 $1.3M 0.07% 166,667 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $1.93B 57 0001104659-26-096982
2026-03-31 2026-05-15 $2.63B 75 0001104659-26-062256
2025-12-31 2026-02-13 $2.32B 60 0001104659-26-015127
2025-09-30 2025-11-14 $1.83B 62 0001104659-25-111551
Filer Information
Address
3000 Sand Hill Road
BUILDING 3-SUITE 150
Menlo Park, CA 94025
Phone
(650) 681-8428
Filing Manager
Sofinnova Investments, Inc.
Menlo Park, CA
Signatory
Nathalie Auber
Attorney-in-Fact